These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

550 related articles for article (PubMed ID: 24708575)

  • 21. Efficacy of bortezomib for reducing donor-specific antibodies in children and adolescents on a steroid minimization regimen.
    Nguyen S; Gallay B; Butani L
    Pediatr Transplant; 2014 Aug; 18(5):463-8. PubMed ID: 24814755
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bortezomib as rescue therapy for antibody mediated rejection: a single-center experience.
    Hardinger KL; Alford K; Murillo D
    Clin Transpl; 2010; ():429-36. PubMed ID: 21696060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial.
    Sautenet B; Blancho G; Büchler M; Morelon E; Toupance O; Barrou B; Ducloux D; Chatelet V; Moulin B; Freguin C; Hazzan M; Lang P; Legendre C; Merville P; Mourad G; Mousson C; Pouteil-Noble C; Purgus R; Rerolle JP; Sayegh J; Westeel PF; Zaoui P; Boivin H; Le Gouge A; Lebranchu Y
    Transplantation; 2016 Feb; 100(2):391-9. PubMed ID: 26555944
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcineurin Inhibitor Minimization With Ixazomib, an Investigational Proteasome Inhibitor, for the Prevention of Antibody Mediated Rejection in a Preclinical Model.
    Reese SR; Wilson NA; Huang G; Redfield RR; Zhong W; Djamali A
    Transplantation; 2015 Sep; 99(9):1785-95. PubMed ID: 25919767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Review of bortezomib treatment of antibody-mediated rejection in renal transplantation.
    Ejaz NS; Alloway RR; Halleck F; Dürr M; Budde K; Woodle ES
    Antioxid Redox Signal; 2014 Dec; 21(17):2401-18. PubMed ID: 24635140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
    Hardinger KL; Murillo D
    Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Effect of Bortezomib on Antibody-Mediated Rejection after Kidney Transplantation.
    Lee J; Kim BS; Park Y; Lee JG; Lim BJ; Jeong HJ; Kim YS; Huh KH
    Yonsei Med J; 2015 Nov; 56(6):1638-42. PubMed ID: 26446648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bortezomib may stabilize pediatric renal transplant recipients with antibody-mediated rejection.
    Pearl MH; Nayak AB; Ettenger RB; Puliyanda D; Palma Diaz MF; Zhang Q; Reed EF; Tsai EW
    Pediatr Nephrol; 2016 Aug; 31(8):1341-8. PubMed ID: 27048228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection-Results of a Cross-Sectional Screening Study.
    Eskandary F; Bond G; Kozakowski N; Regele H; Marinova L; Wahrmann M; Kikić Ž; Haslacher H; Rasoul-Rockenschaub S; Kaltenecker CC; König F; Hidalgo LG; Oberbauer R; Halloran PF; Böhmig GA
    Transplantation; 2017 Mar; 101(3):631-641. PubMed ID: 27120452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preformed donor-specific antibodies and risk of antibody-mediated rejection in repeat renal transplantation.
    Tsapepas DS; Vasilescu R; Tanriover B; Coppleson Y; Rekhtman Y; Hardy MA; Dube G; Crew RJ; Ratner LE; Cohen DJ; Mohan S
    Transplantation; 2014 Mar; 97(6):642-7. PubMed ID: 24637863
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of acute antibody-mediated rejection using bortezomib: a case report.
    Sin YH; Kim YJ; Oh JS; Lee JH; Kim SM; Kim JK
    Nephrology (Carlton); 2015 Jul; 20 Suppl 2():86-9. PubMed ID: 26031595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection.
    Doberer K; Kläger J; Gualdoni GA; Mayer KA; Eskandary F; Farkash EA; Agis H; Reiter T; Reindl-Schwaighofer R; Wahrmann M; Cohen G; Haslacher H; Bond G; Simonitsch-Klupp I; Halloran PF; Böhmig GA
    Transplantation; 2021 Feb; 105(2):451-457. PubMed ID: 32235256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
    Stuckey LJ; Kamoun M; Chan KM
    Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bortezomib for acute humoral rejection treatment at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán in Mexico City: an update.
    Leyva S; Marino LA; Alberú J; Morales-Buenrostro LE
    Clin Transpl; 2010; ():369-82. PubMed ID: 21698837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of antibody-mediated rejection in kidney transplant recipients: a single-center experience with a bortezomib-based regimen.
    Nigos JG; Arora S; Nath P; Hussain SM; Marcus RJ; Ko TY; Sureshkumar KK
    Exp Clin Transplant; 2012 Dec; 10(6):609-13. PubMed ID: 23216567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.
    Everly MJ; Everly JJ; Susskind B; Brailey P; Arend LJ; Alloway RR; Roy-Chaudhury P; Govil A; Mogilishetty G; Rike AH; Cardi M; Wadih G; Tevar A; Woodle ES
    Transplantation; 2008 Dec; 86(12):1754-61. PubMed ID: 19104417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteasome inhibitor treatment of antibody-mediated allograft rejection.
    Woodle ES; Alloway RR; Girnita A
    Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bortezomib use in chronic antibody-mediated allograft dysfunction: updates and additional cases.
    Cooper JE; Wiseman AC; Chan L
    Clin Transpl; 2010; ():415-20. PubMed ID: 21698838
    [No Abstract]   [Full Text] [Related]  

  • 40. Proteasome inhibitor-based therapy for antibody-mediated rejection.
    Walsh RC; Alloway RR; Girnita AL; Woodle ES
    Kidney Int; 2012 Jun; 81(11):1067-74. PubMed ID: 22336990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.